CytoDyn Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. (OTC: CYDY) relating to possible false statements to investors and insider trading by two officers and a director.  In or around March 2020, in the early stages of the COVID-19 pandemic, CytoDyn attempted to pivot its existing drug candidate, leronlimab, which was originally developed for the treatment of HIV, to be used instead as a treatment for severe cases of COVID-19.

SHAREHOLDER ALERT: CytoDyn Inc. (CYDY) Officers and Directors Under Investigation for Possible False Statements and Insider Trading

Gilead Sciences

Failure is not an option for this small-cap biotech developing a COVID-19 treatment.

What's Behind This Wild-Card Coronavirus Stock?

CytoDyn Inc (OTCQB:CYDY) announced that the scientific journal Nature Communications published a study showing that leronlimab prevented nonhuman primates from being infected with Simian Human Immunodeficiency virus (SHIV), a monkey-human chimeric form of HIV.  The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis, or PrEP, therapy to prevent human infection from the virus that causes AIDS, the company said.

CytoDyn sees study of leronlimab preventing Simian Human Immunodeficiency virus published in scientific journal

Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial

Nature Communications Publishes Study of CytoDyn's Leronlimab Preventing HIV Infection in Primates

Alset EHome International

Denison Mines

Verb Technology Company Inc

Finding trending penny stocks in 2021 can be difficult; here's 4 to help you on your search The post Trending Penny Stocks to Buy Right Now? 4 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks to Buy Right Now? 4 For Your Watchlist

CytoDyn: Bulls And Bears Need To Come To Terms On COVID-19 Efforts

CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, revealed that Chiral Pharma Corporation placed its first purchase order for leronlimab under a compassionate special permit (CSP), to treat critically ill coronavirus (COVID-19) patients in the Philippines. The Vancouver, Washington-based late-stage biotech will earn revenue after order fulfillment and the terms of the agreement are ironed out.

CytoDyn wins first buy order from Chiral Pharma for using leronlimab for COVID-19 patients in the Philippines

VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5 antagonist with potential multiple therapeutic indications, announced today a joint collaborative effort with Philippine Airlines as the preferred partner in transporting leronlimab to the Philippines for treatment of critically ill COVID-19 patients.

CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19

Chiral is simultaneously working on application for Emergency Use Authorization

CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines

Investors in a biotech startup developing a COVID-19 treatment claim the firm's leaders cashed out as stock prices surged during a publicity blitz for a drug that has yet to show any value as coronavirus medicine.

Lawsuit: Investors bet big on Washington firm's potential COVID-19 treatment as CEO cashed out

CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, has said that its Brazilian distribution partner Biomm SA (BVMF:BIOM3) plans to submit an authorization request to the Brazilian National Health Surveillance Agency (ANVISA), to conduct two Phase 3 clinical trials of leronlimab in Brazil for coronavirus (COVID-19) patients.  The Vancouver, Washington-based late-stage biotech said the request will be submitted to ANVISA “in the next few days” to conduct two Phase 3 trials for a batch of critically ill COVID-19 patients, and another severely ill population.

CytoDyn says Biomm SA to submit request to conduct Phase 3 clinical studies of leronlimab with ANVISA in Brazil

VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that its Brazilian distribution partner, Biomm S.A. (BVMF: BIOM3), plans to submit an authorization request to the Brazilian National Health Surveillance Agency (“ANVISA”) in the next few days to conduct two Phase 3 clinical trials of leronlimab in Brazil for COVID-19. The two Phase 3 trials consist of trials for each severe and critically ill COVID-19 patients. Once approved by ANVISA, the Phase 3 trials will be conducted by Albert Einstein Israelite Hospital, an Academic Research Organization in Brazil.

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days

CytoDyn Inc (OTCQB:CYDY) has found its new CFO in-house, promoting Vice President, Corporate Controller, Antonio Migliarese, the company announced.  Migliarese joined CytoDyn in January 2020, and he has held various senior financial leadership positions at both public and private companies since 2014, the company said.

CytoDyn taps Vice President, Corporate Controller Antonio Migliarese as its new CFO

VANCOUVER, Washington, May 20, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the promotion of Antonio Migliarese to Chief Financial Officer of the Company. Mr. Migliarese joined CytoDyn in January 2020, and previously served as Vice President, Corporate Controller.

Antonio Migliarese Promoted to Chief Financial Officer of CytoDyn

After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to regulatory agencies, including those in India and the Philippines. Patients in the CD12 trial were administered two doses of leronlimab; on day zero and day seven.

CytoDyn Plans To Send Topline Data From COVID-19 Trial Of Leronlimab To Regulators In India, Philippines

Shares of CytoDyn Inc. were up 0.5% in trading on Tuesday, the day after the Food and Drug Administration issued a statement saying "it has become clear" that the clinical-trial data supplied by the company for its experimental COVID-19 treatment does not "support the clinical benefit of leronlimab." The drug candidate, leronlimab, is a monoclonal antibody being tested in several trials as a treatment for hospitalized COVID-19 patients or those individuals with mild-to-moderate disease.

FDA says data for CytoDyn's experimental COVID-19 therapy does not demonstrate a clinical benefit

CytoDyn Inc (OTCQB:CYDY) plans to submit the topline results of its CD12 Phase 3 clinical trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to regulatory agencies, including those in India and the Philippines.  Patients in the CD12 trial were administered two doses of leronlimab, the first on day zero and another on day seven.

CytoDyn to send topline results from severe coronavirus trial of leronlimab to regulators in India and the Philippines

The FDA has accused CytoDyn Inc (OTC: CYDY) of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is effective. In March, the Phase 3 trial of CytoDyn's leronlimab failed on the primary goal of reducing symptoms and all secondary goals, including one that questioned whether the therapy could reduce mortality.

CytoDyn Stock Falls After FDA Rebukes Claims On COVID-19 Treatment

Finalized data analysis shows CD12 trial reached almost all of its major secondary  endpoints in a subpopulation (62 patients) of critically ill COVID-19

CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines

VANCOUVER, Washington, May 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Chris Recknor, M.D., Chief Operating Officer will host an investment community webcast on Tuesday, May 18, 2021.

CytoDyn to Hold Webcast on May 18 to Discuss FDA's Statement on Leronlimab

Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn" or "the Company") (OTCQB: CYDY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 27, 2020 and March 9, 2021, inclusive (the...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - May 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 and March 9, 2021, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased CytoDyn securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

CYDY Final Deadline Today: Rosen, National Trial Lawyers, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action - CYDY

CytoDyn recently executed supply and distribution agreements for leronlimab in the Philippines, Brazil, and India. I believe these partnerships improve CytoDyn's long-term outlook. Leronlimab now has an Ex-U.S. distribution network that covers roughly 20% of the world's population. I believe this network will be critical for COVID-19 and additional indications.

CytoDyn: Recent Leronlimab Agreements Improve My Long-Term Outlook

New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytoDyn Inc. ("CytoDyn") (OTCQB: CYDY) between March 27, 2020 and March 9, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Washington. To get more information go...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytoDyn Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - CYDY

New York, New York--(Newsfile Corp. - May 15, 2021) - WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 and March 9, 2021, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased CytoDyn securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

CYDY Final Deadline Notice: Rosen, A Leading Law Firm, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action - CYDY

News for CytoDyn Inc. Stock (CYDY)